 Participants are randomly assigned to receive a single dose of Ketamine 0.5 mgkg or Midazolam 0.02 mgkg, which is given slowly, in a vein, over about 40 minutes. The study is double-blind, meaning patients and study staff will not know which medication is in the infusion. 